Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial

Clemens M. Wendtner, Michael Hallek, Graeme A.M. Fraser, Anne Sophie Michallet, Peter Hillmen, Jan Dürig, Matt Kalaycio, John G. Gribben, Stephan Stilgenbauer, Andreas Buhler, Thomas J. Kipps, Brendan Purse, Jennie Zhang, Sabine De Bedout, Jay Mei, Asher Chanan-Khan

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences